Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Myelodysplastic Syndrome (MDS) Drugs Market

Myelodysplastic Syndrome (MDS) Drugs Market Share

Report ID: GMI10852
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Myelodysplastic Syndrome Drugs Market Share

The myelodysplastic syndrome drugs industry is driven by continuous innovation and technological advancements. Leading companies offer a range of advanced treatments, including medications, alongside strategic initiatives to stay competitive. Significant investments in research and development are crucial for introducing new products and enhancing existing ones. Key drivers include the development of novel therapies such as immunomodulatory and targeted treatments. Continuous advancements in drug development and treatment methodologies are expected to propel market growth, providing patients with more effective options and improving overall treatment outcomes for MDS.

Myelodysplastic Syndrome Drugs Market Companies

Few of the prominent players operating in myelodysplastic syndrome drugs industry include:

Amgen Inc.
Astex Pharmaceuticals, Inc.
Bristol-Myers Squibb Company (Celgene Corporation)
Cipla Limited
Dr. Reddy's Laboratories Inc.
Hikma Pharmaceuticals PLC
Johnson & Johnson Services, Inc.
Lupin Limited
Otsuka America Pharmaceutical, Inc.
Pfizer, Inc.
Sandoz
Shilpa Medicare Limited
Sun Pharmaceutical Industries, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Myelodysplastic syndrome drugs market size was USD 2.8 billion in 2023 and is expected to register 8% CAGR from 2024-2032 owing to increasing incidence of MDS, particularly among the aging population worldwide.

Myelodysplastic syndrome drugs industry from the hypomethylating drugs segment reached USD 1.5 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to their ability to improve survival rates.

North America myelodysplastic syndrome drugs industry reached USD 1.2 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to a high prevalence of disease, advanced healthcare infrastructure, and significant healthcare expenditure in the region.

Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Sandoz, Shilpa Medicare Limited, Sun Pharmaceutical Industries, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd, are some of the major myelodysplastic syndrome (MDS) drugs companies worldwide.